The timing and treatment modality of early oligorecurrent prostate cancer (PCa) that is visible only on prostate-specific membrane antigen (PSMA) imaging remains a matter of debate [1], [2], [3]. This evidence concerns the gene FOLH1 and prostate carcinoma.